

IN THE CLAIMS

Please amend claims 1 and 5 as follows:

1. (Currently Amended) A method of identifying a candidate psychiatric patient for treatment with atypical antipsychotic or antidepressant medication that acts at a D2 dopamine receptor (DRD2) or influences D2 dopamine receptor density, the method comprising:

determining whether the patient's DRD2 genotype is Taq1A allele positive (A1+) or Taq1A allele negative (A1-); wherein:

an A1+ genotype is indicative of a candidate for treatment with ~~high-dose-high~~ low-dose DRD2 binding atypical antipsychotics and/or SSRIs ~~that increase D2-dopamine-receptor density;~~ and

an A1- genotype is indicative of a candidate for treatment with ~~low-dose~~ high dose or-low D2 dopamine receptor binding atypical antipsychotics or alternative antidepressant.

2. (Original) The method of claim 1, wherein the psychiatric patient suffers from schizophrenia.

3. (Original) The method of claim 1, wherein the patient suffers from post-traumatic stress disorder (PTSD), depression, social anxiety or mixed anxiety and depressive states.

4. (Original) The method of claim 1, wherein the patient suffers from Parkinson's disease.

5. (Currently Amended) The method of claim 1, wherein the high DRD2 binding atypical antipsychotic is risperidone.

6. (Previously Presented) The method of claim 1, wherein the SSRI is paroxetine.